Semaglutide vs Wegovy: The Research Peptide and the Branded Medication
Wegovy and semaglutide are frequently searched together, and the relationship between them is a common source of confusion. Wegovy is an approved prescription medicine, and its active ingredient is semaglutide. The semaglutide sold as a research peptide is that same molecule, supplied for laboratory study rather than as a medicine. A further wrinkle is that semaglutide is the active ingredient in more than one brand, so this article explains what Wegovy is, how it relates to the research peptide, and how it differs from the other well-known semaglutide product.
One molecule, more than one brand
Semaglutide is a GLP-1 receptor agonist, a 31-amino-acid analog of the human GLP-1 hormone. Novo Nordisk markets it under two different brand names for two different approved purposes: one is directed at glycemic control in type 2 diabetes, and Wegovy is directed at chronic weight management. The molecule is the same in each; what changes between the brands is the approved indication and the dosing schedule set out in each product monograph. The semaglutide and Ozempic comparison looks at the diabetes-focused brand in the same way.
What Wegovy is
Wegovy is a brand-name prescription medication from Novo Nordisk, and Wegovy is a registered trademark of Novo Nordisk named here only for identification. In Canada it is approved by Health Canada for chronic weight management in adults, used alongside diet and physical activity, and it is supplied as a pre-filled subcutaneous pen dispensed by prescription. As a finished pharmaceutical it is manufactured under good-manufacturing-practice standards, carries an approved product monograph, and is prescribed and monitored by a clinician.
What the research peptide is
The semaglutide sold as a research peptide is the same base molecule supplied as a lyophilized powder and labeled research use only. It is not a medicine, is not prescribed, and is not intended for human or veterinary use. Rather than a product monograph, it is accompanied by a per-batch certificate of analysis that documents identity and purity for laboratory purposes. It is reconstituted and measured at the bench as a research material, not administered as a treatment.
Side by side
| Attribute | Wegovy (branded medication) | Semaglutide (research peptide) |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide |
| Category | Approved prescription medicine | Research-use-only material |
| Approved purpose | Chronic weight management in adults | None, laboratory research only |
| Regulatory status | Health Canada approved, product monograph | Not approved for human use |
| Form | Pre-filled subcutaneous pen | Lyophilized powder in a vial |
| Documentation | Approved monograph, prescription | Per-batch certificate of analysis |
| Intended use | Clinical treatment under prescription | Laboratory research only |
The distinction that matters
Sharing an active molecule does not make Wegovy and a research peptide interchangeable. Wegovy is a regulated medicine with an approved weight-management indication, a controlled supply chain, and clinical oversight. A research peptide is laboratory material with no approved human use. Nothing here should be read as encouragement to use research material in place of a prescribed medication or for any human purpose. Anyone considering treatment for weight or metabolic health should discuss approved options with a licensed healthcare professional, which is a medical decision and not a research one.
Approved generics add a third category
Canada has now approved generic semaglutide as well. A generic is still an approved, regulated pharmaceutical, so it belongs in the same medicine category as Wegovy rather than with research material. Holding the three apart keeps the picture accurate: a brand medicine, an approved generic medicine, and a research-use-only peptide are distinct things even when the molecule inside them is identical. Conflating a research peptide with any of the approved products is the error this comparison is meant to prevent.
The molecule as a research subject
Within research, semaglutide is studied for GLP-1 receptor pharmacology and as a benchmark against other incretin compounds. The semaglutide research overview describes its structure and mechanism, and the metabolic research overview places it among related compounds. Identity and purity for the research material are confirmed on the certificate of analysis page, reconstitution math is handled with the reconstitution calculator, and current stock is in the store.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.